IFP Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.5M | Buy |
228,411
+28,014
| +14% | +$733K | 0.1% | 220 |
|
|
2026
Q1 | $5.63M | Sell |
200,397
-9,475
| -5% | -$252K | 0.12% | 198 |
|
|
2025
Q4 | $5.23M | Sell |
209,872
-96
| -0% | -$2.42K | 0.12% | 186 |
|
|
2025
Q3 | $5.35M | Sell |
209,968
-3,577
| -2% | -$88.3K | 0.14% | 164 |
|
|
2025
Q2 | $5.22M | Buy |
213,545
+12,206
| +6% | +$285K | 0.15% | 150 |
|
|
2025
Q1 | $5.1M | Sell |
201,339
-30,766
| -13% | -$805K | 0.16% | 144 |
|
|
2024
Q4 | $6.16M | Buy |
232,105
+107,688
| +87% | +$2.92M | 0.2% | 102 |
|
|
2024
Q3 | $3.6M | Buy |
124,417
+5,965
| +5% | +$174K | 0.13% | 165 |
|
|
2024
Q2 | $3.31M | Buy |
118,452
+56,077
| +90% | +$1.54M | 0.13% | 157 |
|
|
2024
Q1 | $1.73M | Buy |
62,375
+13,294
| +27% | +$369K | 0.08% | 281 |
|
|
2023
Q4 | $1.41M | Sell |
49,081
-8,270
| -14% | -$250K | 0.07% | 313 |
|
|
2023
Q3 | $1.9M | Sell |
57,351
-11,409
| -17% | -$403K | 0.09% | 242 |
|
|
2023
Q2 | $2.52M | Sell |
68,760
-5,009
| -7% | -$195K | 0.11% | 203 |
|
|
2023
Q1 | $2.5M | Sell |
73,769
-85,933
| -54% | -$3.71M | 0.11% | 195 |
|
|
2022
Q4 | $5.46M | Sell |
159,702
-17,157
| -10% | -$823K | 0.15% | 126 |
|
|
2022
Q3 | $6.11M | Buy |
176,859
+24,928
| +16% | +$1.21M | 0.16% | 127 |
|
|
2022
Q2 | $5.18M | Hold |
151,931
| – | – | 0.17% | 132 |
|
|
2022
Q1 | $5.18M | Buy |
151,931
+68,040
| +81% | +$3.53M | 0.17% | 132 |
|
|
2021
Q4 | $4.96M | Sell |
83,891
-6,159
| -7% | -$305K | 0.1% | 115 |
|
|
2021
Q3 | $3.88M | Buy |
90,050
+14,230
| +19% | +$630K | 0.08% | 160 |
|
|
2021
Q2 | $2.97M | Buy |
75,820
+6,924
| +10% | +$269K | 0.06% | 180 |
|
|
2021
Q1 | $2.49M | Sell |
68,896
-63,213
| -48% | -$2.24M | 0.05% | 194 |
|
|
2020
Q4 | $4.87M | Sell |
132,109
-1,157
| -0.9% | -$42.4K | 0.2% | 90 |
|
|
2020
Q3 | $4.65M | Buy |
133,266
+8,726
| +7% | +$306K | 0.28% | 71 |
|
|
2020
Q2 | $3.87M | Buy |
124,540
+56,463
| +83% | +$1.92M | 0.31% | 71 |
|
|
2020
Q1 | $2.06M | Buy |
68,077
+7,594
| +13% | +$259K | 0.21% | 114 |
|
|
2019
Q4 | $2.27M | Sell |
60,483
-27,657
| -31% | -$985K | 0.17% | 139 |
|
|
2019
Q3 | $3.03M | Buy |
+88,140
| New | +$3.21M | 0.2% | 110 |
|
|
2019
Q1 | $1.53M | Sell |
38,036
-156,459
| -80% | -$6.27M | 0.21% | 106 |
|
|
2018
Q4 | $7.93M | Sell |
194,495
-55,119
| -22% | -$2.29M | 0.48% | 37 |
|
|
2018
Q3 | $10.4M | Sell |
249,614
-15,213
| -6% | -$586K | 0.43% | 43 |
|
|
2018
Q2 | $9.12M | Sell |
264,827
-6,024
| -2% | -$206K | 0.38% | 51 |
|
|
2018
Q1 | $9.31M | Hold |
270,851
| – | – | 0.42% | 43 |
|
|
2017
Q4 | $9.31M | Sell |
270,851
-123,478
| -31% | -$4.21M | 0.42% | 43 |
|
|
2017
Q3 | $13.4M | Sell |
394,329
-3,343
| -0.8% | -$107K | 0.53% | 29 |
|
|
2017
Q2 | $12.7M | Buy |
397,672
+14,437
| +4% | +$455K | 0.54% | 26 |
|
|
2017
Q1 | $12.4M | Buy |
383,235
+86,508
| +29% | +$2.73M | 0.54% | 25 |
|
|
2016
Q4 | $9.14M | Buy |
296,727
+28,250
| +11% | +$862K | 0.44% | 39 |
|
|
2016
Q3 | $8.63M | Sell |
268,477
-8,958
| -3% | -$300K | 0.45% | 38 |
|
|
2016
Q2 | $9.27M | Buy |
277,435
+239,399
| +629% | +$7.64M | 0.52% | 27 |
|
|
2016
Q1 | $1.53M | Sell |
38,036
-230,887
| -86% | -$6.6M | 0.21% | 106 |
|
|
2015
Q4 | $8.24M | Buy |
+268,923
| New | +$8.46M | 0.55% | 34 |
|
Other funds holding PFE
IFP Advisors's PFE Position: Q2 2026 in Review
IFP Advisors increased its Pfizer (PFE) stake by 14% in Q2 2026, buying an estimated $733K and bringing the position to 228,411 shares worth $5.5M. The position accounts for 0.1% of the portfolio, ranked #220.
IFP Advisors first reported a position in PFE in Q4 2015 and has held it in 42 quarters since. The position peaked at $13.4M in Q3 2017. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- IFP Advisors held 228,411 shares of Pfizer worth $5.5M as of Q2 2026.
- IFP Advisors bought 28,014 Pfizer shares in Q2 2026, an estimated $733K.
- Pfizer made up 0.1% of IFP Advisors's portfolio in Q2 2026, its #220 holding.
- IFP Advisors first reported a position in Pfizer in Q4 2015 and has held it in 42 quarters since.
- IFP Advisors's Pfizer position peaked at $13.4M in Q3 2017.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.